Risk of neutropenia and healthcare resource utilization in patients with metastatic breast cancer treated with CDK4/6 inhibitors in real-world setting
Introduction: In patients with metastatic estrogen-receptor (ER) positive breast cancer, the current standard of care as first or second line treatment is a combination of endocrine therapy with a CDK 4/6-inhibitor. Neutropenia is a dose-limiting toxicity of CDK 4/6 inhibitors leading to dose adjust...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
Örebro universitet, Institutionen för medicinska vetenskaper
2021
|
| Subjects: | |
| Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-91411 |